0001752724-19-188845.txt : 20191212
0001752724-19-188845.hdr.sgml : 20191212
20191211174218
ACCESSION NUMBER: 0001752724-19-188845
CONFORMED SUBMISSION TYPE: N-CEN
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20190930
FILED AS OF DATE: 20191212
DATE AS OF CHANGE: 20191211
EFFECTIVENESS DATE: 20191212
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: TEKLA HEALTHCARE INVESTORS
CENTRAL INDEX KEY: 0000805267
IRS NUMBER: 046564285
STATE OF INCORPORATION: MA
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: N-CEN
SEC ACT: 1940 Act
SEC FILE NUMBER: 811-04889
FILM NUMBER: 191280522
BUSINESS ADDRESS:
STREET 1: 100 FEDERAL STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 6177728515
MAIL ADDRESS:
STREET 1: 100 FEDERAL STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02110
FORMER COMPANY:
FORMER CONFORMED NAME: H&Q HEALTHCARE INVESTORS
DATE OF NAME CHANGE: 19920703
N-CEN
1
primary_doc.xml
X0201
N-CEN
LIVE
0000805267
XXXXXXXX
811-04889
false
false
false
N-2
TEKLA HEALTHCARE INVESTORS
811-04889
0000805267
549300SNASESIFOS6V75
100 FEDERAL STREET,
19TH FLOOR
BOSTON
02110
US-MA
US
617-772-8500
State Street Bank and Trust Company
1 Lincoln Street
Boston
02111
617-786-3000
Accounting and Custody Records
Tekla Capital Management LLC
100 Federal Street
19th Floor
Boston
02110
617-772-8500
Fund Administration Records
N
N
N-2
N
Thomas M Kent, CPA
000000000
N
Daniel R. Omstead, Ph.D.
000000000
Y
Lucinda H. Stebbins, M.B.A., CPA
000000000
N
William S. Reardon, M.B.A.
000000000
N
Rakesh K. Jain, Ph.D.
000000000
N
Oleg M. Pohotsky, M.B.A., J.D.
000000000
N
Laura Woodward, CPA
000000000
100 Federal Street
19th Floor
Boston
02110
XXXXXX
N
N
N
N
N
N
Deloitte & Touche LLP
34
00000000000000000000
N
N
N
N
N
N
TEKLA HEALTHCARE INVESTORS
549300SNASESIFOS6V75
N
0
0
0
N/A
Y
N
N
N
N/A
N/A
N/A
Rule 17a-6 (17 CFR 270.17a-6)
N
N
N
N
Tekla Capital Management LLC
801-61018
000119626
254900YSXGYL9SE8C952
N
Computershare Trust Company, National Association
85-11340
2549001YYB62BVMSAO13
N
N
N
ICE Data Services, Inc.
13-3668779
Tax ID
N
Refinitiv US Holdings Inc.
549300NF240HXJO7N016
N
N
Credit Suisse (Schweiz) AG
549300CWR0W0BCS9Q144
CH
N
Y
Foreign custodian - rule 17f-5 (17 CFR 270.17f-5)
Clearstream Banking S.A.
549300OL514RA0SXJJ44
LU
N
Y
Foreign securities depository - rule 17f-7 (17 CFR 270.17f-7)
State Street Bank and Trust Company (Edinburgh, GB, Branch)
571474TGEMMWANRLN572
GB
N
Y
Foreign custodian - rule 17f-5 (17 CFR 270.17f-5)
State Street Bank and Trust Company (Boston, MA, US, Branch)
571474TGEMMWANRLN572
N
N
Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1))
Deutsche Bank Aktiengesellschaft (Amsterdam, Noord Holland, NL, Branch)
7LTWFZYICNSX8D621K86
NL
N
Y
Foreign custodian - rule 17f-5 (17 CFR 270.17f-5)
N
Computershare Trust Company, National Association
2549001YYB62BVMSAO13
N
N
N
State Street Bank and Trust Company (Boston, MA, US, Branch)
571474TGEMMWANRLN572
N
N
N
Jefferies LLC
8-15074
000002347
58PU97L1C0WSRCWADL48
48973.02
Morgan Stanley & Co. LLC
8-15869
000008209
9R7GPTSO7KV3UQJZQ078
11839.5
Wells Fargo Securities, LLC
8-65876
000126292
VYVVCKR63DVZZN70PB21
22954.44
Pershing LLC
8-17574
000007560
ZI8Q1A8EI8LQFJNM0D94
63741.12
J.P. Morgan Securities LLC
8-35008
000000079
ZBUT11V806EZRVTWT807
76727.01
Sanford C. Bernstein & Co., LLC
8-52942
000104474
549300I7JYZHT7D5CO04
22350.15
National Financial Services LLC
8-26740
000013041
549300JRHF1MHHWUAW04
70779.69
Citigroup Global Markets Inc.
8-8177
000007059
MBNUM2BPBDO7JBLYG310
9818.88
Mizuho Securities USA LLC
8-37710
000019647
7TK5RJIZDFROZCA6XF66
23809.83
Oppenheimer & Co. Inc.
8-4077
000000249
254900VH02JQR2L8XD64
9020.1
391725.67
Rainier Therapeutics, Inc.
N/A
000000000
00000000000000000000
1395282.74
Pershing LLC
8-17574
000007560
ZI8Q1A8EI8LQFJNM0D94
1394992.5
Milestone Pharmaceuticals Inc.
N/A
000000000
00000000000000000000
CA
1909089.77
Oculis SA
N/A
000000000
00000000000000000000
CH
2099896.18
State Street Bank and Trust Company
N/A
000000000
571474TGEMMWANRLN572
5345195000
Labcyte Inc.
N/A
000000000
00000000000000000000
7524854.36
Arkuda Therapeutics, Inc.
N/A
000000000
00000000000000000000
MA
1909092.78
Veniti, Inc.
N/A
000000000
00000000000000000000
5421306.95
Therachon AG
N/A
000000000
00000000000000000000
CH
14723214.55
J.P. Morgan Securities LLC
8-35008
000000079
ZBUT11V806EZRVTWT807
79529746.12
5466717662.85
N
937128803.87
Common stock
Tekla Healthcare Investors
N
N
Common stock
N
N
N
0.94
1.12
18.34000000
20.33
true
INTERNAL CONTROL RPT
2
NCEN_1346434620711760.txt
REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM
To the Shareholders and Board of Trustees of Tekla
Healthcare Investors
In planning and performing our audit of the financial
statements of Tekla Healthcare Investors (the "Fund")
as of and for the year ended September 30, 2019, in
accordance with the standards of the Public Company
Accounting Oversight Board (United States) (PCAOB),
we considered the Fund's internal control over financial
reporting, including controls over safeguarding
securities, as a basis for designing our auditing
procedures for the purpose of expressing our opinion
on the financial statements and to comply with the
requirements of Form N-CEN, but not for the purpose of
expressing an opinion on the effectiveness of the Fund's
internal control over financial reporting. Accordingly,
we express no such opinion.
The management of the Fund is responsible for
establishing and maintaining effective internal control
over financial reporting. In fulfilling this responsibility,
estimates and judgments by management are required
to assess the expected benefits and related costs of
controls. A fund's internal control over financial
reporting is a process designed to provide reasonable
assurance regarding the reliability of financial reporting
and the preparation of financial statements for external
purposes in accordance with generally accepted
accounting principles. A fund's internal control over
financial reporting includes those policies and
procedures that (1) pertain to the maintenance of
records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of
the fund; (2) provide reasonable assurance that
transactions are recorded as necessary to permit
preparation of financial statements in accordance with
generally accepted accounting principles, and that
receipts and expenditures of the fund are being made
only in accordance with authorizations of management
and trustees of the fund; and (3) provide reasonable
assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of a fund's
assets that could have a material effect on the financial
statements.
Because of its inherent limitations, internal control over
financial reporting may not prevent or detect
misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk
that controls may become inadequate because of
changes in conditions or that the degree of compliance
with the policies or procedures may deteriorate.
A deficiency in internal control over financial reporting
exists when the design or operation of a control does
not allow management or employees, in the normal
course of performing their assigned functions, to
prevent or detect misstatements on a timely basis. A
material weakness is a deficiency, or a combination of
deficiencies, in internal control over financial reporting,
such that there is a reasonable possibility that a
material misstatement of a fund's annual or interim
financial statements will not be prevented or detected
on a timely basis.
Our consideration of the Fund's internal control over
financial reporting was for the limited purpose
described in the first paragraph and would not
necessarily disclose all deficiencies in internal control
that might be material weaknesses under standards
established by the PCAOB. However, we noted no
deficiencies in the Fund's internal control over financial
reporting and its operation, including controls for
safeguarding securities that we consider to be a
material weakness, as defined above, as of September
30, 2019.
This report is intended solely for the information and
use of management and the Board of Trustees of the
Fund and the Securities and Exchange Commission and
is not intended to be and should not be used by anyone
other than these specified parties.
/s/ DELOITTE & TOUCHE LLP
Boston, Massachusetts
November 22, 2019